- Pieris Pharmaceuticals Inc PIRS has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat idiopathic pulmonary fibrosis (IPF).
- The Company will also receive a €14.2 million (approximately $17 million) grant from the Bavarian Ministry of Economic Affairs, Regional Development, and Energy to research and develop PRS-220 for post-acute COVID-19 pulmonary fibrosis, also known as pulmonary fibrosis secondary to COVID-19 or "long COVID."
- Clinical development of the program for both indications is expected to begin next year.
- Price Action: PIRS shares are up 12.8% at $4.93 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechGovernmentNewsPenny StocksHealth CareFinancingGeneralBriefsidiopathic pulmonary fibrosis
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
